FoxP3+, and not CD25+, T cells increase post-transplant in islet allotransplant recipients following anti-CD25+ rATG immunotherapy
- 作者：Kelly Hire ; Diem K. Ngo ; Kristen M. Stewart-Maynard ; Bernhard Hering ; Pratima Bansal-Pakala ; bansa006@umn.edu
- 关键词：Tregs ; regulatory T cells ; PBMC ; peripheral blood mononuclear cells ; OPD ; o-phenylenediamine dihydrochloride ; BSA ; bovine serum albumin
- 刊名：Cellular Immunology
- 出版年：2012
- 期刊代码：279_00088749
- 类别：med
- 出版时间：2012
- 卷：274
- 期：1-2
- 页码：83-88
- 文件大小：449 K
摘要
Anti-CD25 antibodies are used as an induction therapy in islet allotransplantation for type 1 diabetes. Although previous reports suggested that anti-CD25 treatment may lead to depletion of CD4+CD25+ regulatory T cells (Tregs) and questioned its use in tolerance-promoting protocols for transplantation, the effect of anti-CD25 antibodies on the frequency and function of Tregs remains unclear. We examined the effect of anti-CD25 antibody, daclizumab, in vivo on Tregs in islet allograft recipients enrolled in a single-center study and monitored post-transplant. Our data shows that the reduction in CD25+ Treg cells observed post-transplant is due to masking of CD25 receptor by daclizumab and not due to depletion. In addition, using Treg marker, FoxP3, we show that anti-CD25+ ATG treatment leads to an increase in FoxP3+ Tregs post-transplant. These data suggest that anti-CD25-based therapy has beneficial effects on Tregs and combined with ATG may be a promising therapy for autoimmunity and transplantation.